317318-96-0

Basic information

• Product Name: (4-METHYL-2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL
• Synonyms: (4-METHYL-2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL;5-(Hydroxymethyl)-4-methyl-2-(4-trifluoromethylphenyl)thiazole;[4-Methyl-2-(4-trifluoroMethylphenyl)thiazol-5-yl]Methanol;[4-Methyl-2-[4-(trifluoroMethyl)phenyl]-1,3-thiazol-5-yl]Methano;4-Methyl-2-[4-(trifluoroMethyl)phenyl]-5-thiazoleMethanol;[4- methyl -2- (4- (three fluorine methyl) phenol) -1,3- thiazole -5- based methanol;[4- Methyl -2- (4- (Three Fluorine Methyl Phenol -1,3- Thiazole -5- Based Methano
• CAS NO: 317318-96-0
• Molecular Formula: C₁₂H₁₀F₃NOS
• Molecular Weight: 273.27
• EINECS: 200-589-5
• Product Categories: Intermediates & Fine Chemicals;Pharmaceuticals;Sulfur & Selenium Compounds
• Mol File: 317318-96-0.mol
• Article Data: 18

Chemical Properties

• Melting Point: 120-123°C
• Boiling Point: 380°Cat760mmHg
• Flash Point: 183.6°C
• Appearance: /
• Density: 1.359g/cm³
• Vapor Pressure: 1.89E-06mmHg at 25°C
• Refractive Index: 1.545
• Storage Temp.: -20°C Freezer
• Solubility: Chloroform (Slightly), Methanol (Slightly)
• PKA: 13.47±0.10(Predicted)
• CAS DataBase Reference: (4-METHYL-2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL(CAS DataBase Reference)
• NIST Chemistry Reference: (4-METHYL-2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL(317318-96-0)
• EPA Substance Registry System: (4-METHYL-2-[4-(TRIFLUOROMETHYL)PHENYL]-1,3-THIAZOL-5-YL)METHANOL(317318-96-0)

Safety Data

• HazardClass: IRRITANT
• Hazardous Substances Data: 317318-96-0(Hazardous Substances Data)

Usage

InChI:InChI=1/C12H10F3NOS/c1-7-10(6-17)18-11(16-7)8-2-4-9(5-3-8)12(13,14)15/h2-5,17H,6H2,1H3

Upstream product

• 873066-26-3 [4-bromo-2-(4-trifluoromethylphenyl)thiazol-5-yl]methanol 
• 594-27-4 tetramethylstannane 
• 16853-85-3 lithium aluminium tetrahydride 
• 1514-09-6 4-(trifluoromethyl)benzothioic S-acid 
• 1891-90-3 p-trifluoromethylbenzamide 
• 144059-86-9 4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole-5-carboxylic acid 
• 853076-90-1 4-ethyl-2-(4-trifluoromethyl-phenyl)thiazole-5-carboxylic acid ethyl ester 
• 86487-19-6 tributyl(4-(trifluoromethyl)phenyl)stannane 
• 402-43-7 p-trifluoromethylphenyl bromide 
• 873066-23-0 4-trifluoromethylphenylboronic dimethyl ester 
• 72505-21-6 4-trifluoromethylbenzthioamide 
• 175277-03-9 4-methyl-2-[4-(trifluoromethyl)phenyl]thiazole-5-carboxylic acid ethyl ester 

Downstream Products

• 866531-10-4 4-([4-methyl-2-(4-trifluoromethyl-phenyl)-thiazol-5-yl]-methoxymethyl)-benzoic acid methyl ester 
• 636589-63-4 4-{{2-[4-(trifluoromethyl)phenyl]-4-methylthiazol-5-yl}methylthio}-2-methylphenol 
• 343322-83-8 ethyl 2-{4-{{2-[4-(trifluoromethyl)phenyl]-4-methylthiazol-5-yl}methylthio}-2-methylphenoxy}acetate 
• 866920-28-7 2-Fluoro-N-hydroxy-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole-5-ylmethoxy]-benzamidine 
• 866920-21-0 3-{2-fluoro-4-[4-methyl-2-(4-trifluoromethyl-phenyl)-thiazole-5-ylmethoxyl-phenyl]}-4H-[1,2,4]oxadiazole-5-one 
• 1428183-86-1 C₂₀H₁₇F₃N₂O₃S 
• 1202576-69-9 ethyl 3-ethoxy-3-[4-({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methoxy)phenyl]propionate 
• 317318-97-1 5-(chloromethyl)-4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazole 
• 317318-69-7 methyl [2-methyl-4-[[[4-methyl-2-[4-(trifluoromethyl)phenyl]thiazol-5-yl]methyl]sulfanyl]peroxy]acetate 
• 317318-65-3 methyl 2-{4-[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)sulfanyl]phenoxy}acetate 
• 929693-87-8 ethyl 2-methyl-2-[(4-{[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)amino]carbonyl}phenyl)oxy]propanoate 
• 929693-62-9 ethyl 2-methyl-2-[(4-{[({4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}methyl)amino]methyl}phenyl)oxy]propanoate 
• 929693-56-1 ethyl [2-methyl-4-(2-{4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}ethyl)phenoxy]acetate 
• 439134-90-4 ethyl (E/Z)-[2-methyl-4-(2-{4-methyl-2-[4-(trifluoromethyl)phenyl]-1,3-thiazol-5-yl}ethenyl)phenoxy]acetate 

Relevant articles and documents

Synthesis of thiazole linked chalcones and their pyrimidine analogues as anticancer agents

A series of nine novel thiazole linked chalcones, (E)-3-(4-methyl-2-(4(trifluoromethyl)phenyl)thiazol-5-yl)-1-phenylprop-2-en-1-one derivatives 7–15 were synthesized. To establish the structure–activity relationship (SAR), furthermore, the corresponding, ring-closed pyrimidine analogs 17–23 were synthesized. The derivatives thus obtained were evaluated for their anti-cancer activity against three genetically different colorectal cancer (CRC) cell lines. Thiazole derivatives 7, 9, and10 showed anti-cancer activity with GI50 values ranging from 0.19 to 100 μM. Importantly, compounds 7 and 10 outperformed the standard drug cisplatin in the tested cell lines and thus show promise for further optimization. Some of pyrimidine derivatives retain activity comparable to cisplatin in the HT-29 cell line, e.g. compounds 17 and 18 with IC50 of 25?μM, however, none of these compounds demonstrated improved antiproliferative activity as compared with the starting thiazole, thus the enone linker was critical for obtaining more active compounds in this series.

Synthesis and Evaluation of PPARδAgonists That Promote Osteogenesis in a Human Mesenchymal Stem Cell Culture and in a Mouse Model of Human Osteoporosis

We synthesized a directed library of compounds to explore the structure-activity relationships of peroxisome proliferator-activated receptor δ(PPARδ) activation relative to mesenchymal stem cell (MSC) osteogenesis. Our scaffold used para-substituted cinnamic acids as a polar headgroup, a heteroatom and heterocycle core connecting units, and substituted phenyl groups for the lipophilic tail. Compounds were screened for their ability to increase osteogenesis in MSCs, and the most promising were examined for subunit specificity using a quantitative PPAR transactivation assay. Six compounds were selected for in vivo studies in an ovariectomized mouse model of human postmenopausal osteoporosis. Four compounds improved bone density in vivo, with two (12d and 31a) having activity comparable to that of GW0742, a well-studied PPARδ-selective agonist. 31a (2-methyl-4-[N-methyl-N-[5-methylene-4-methyl-2-[4-(trifluoromethyl)phenyl]thiazole]]aminocinnamic acid) had the highest selectivity for PPARδcompared to other subtypes, its selectivity far exceeding that of GW0742. Our results confirm that PPARδis a new drug target for possible treatment of osteoporosis via in situ manipulation of MSCs.

ANALOGS OF PPARO AND 20-OH-PGE2, AND METHODS OF USING THE SAME

Analogs of PPAR5 and analogs of 20-OH-PGE2, which are PPAR5 agonists and 20-OH-PGE2 antagonists, respectively, and methods of using the same for inducing osteogenesis or chondrogenesis, are disclosed.